Venu
Position Trader, Market Leaders, Fundamental/Technical Analysis
Hinge Health's revenue growth and cash generation strengthen its case as a leading non-tech IPO near all-time highs. The attached portfolio-stock analysis projects 46% revenue growth in 2026 and puts Q2 free cash flow at about $100 million, roughly three times the year-earlier level. It lists further revenue and margin expansion as potential catalysts. x.com x.comÂ
Hinge Health is fine because money has been funneling into healthcare and out of tech, and the raised-guidance catalyst is now behind it. The stock bounced off its 9-day EMA. x.comÂ
Hinge Health is the best name in healthcare information, the hottest industry of the past quarter. Strong new contracts with health plans have boosted its margins significantly, while good cash flow and conservative leverage add a margin of safety. x.comÂ
Cerebras shares face selling pressure as a sizable unlock hits its tiny float. Per the prospectus, about 28 million Class A shares held by directors, officers and non-employee holders become tradable on the second trading day after Tuesday's earnings, only about three months after listing. With IPOs coming years later, VC and PE backers collect the gains while retail becomes exit liquidity, needing seven years of 70% revenue growth to justify the valuation. x.com x.comÂ
Cerebras fits the pattern of many recent IPOs: a low float plus retail FOMO produces a high valuation that then bleeds down over months. As @aleabitoreddit puts it, it is a good company but hard to like at a ~$90-100 billion market cap, and float dynamics could keep it at absurd valuations for a short time before things correct. x.comÂ
The coming IPO wave led by SpaceX, OpenAI and Anthropic will create wealth that must flow through exchanges, brokers, wealth and alternative managers and luxury brands, still valued below peaks. Rebalancing, margin loans and estate plans run on the same rails that handled the offerings. SpaceX alone brought about $500M in underwriting fees to Goldman Sachs and Morgan Stanley, and Nasdaq's fast-entry rule forces index buying within 15 days. In the 1990s this plumbing scaled with the money. x.com … Show more
Cerebras risks falling further if the market takes a breather, because stocks that IPO in a red-hot bull market tend to get bid far above fair value and then drop precipitously, as Arm's IPO showed; Cerebras has already fallen some. Investors upset about missing an allocation should remember this, echoing @ram's point, relayed by @dee_bosa, that every stock gets back to its IPO price. x.comÂ
Cerebras could draw a rush of capital as one of the year's biggest IPOs, touted as an Nvidia killer, with memory names likely hit as money rotates. Priced at $185 after an initial $115-125 range, it trades thinly near $285 pre-listing. A low float with IPO lockups and heavy allocation to long-only funds tends to produce a strong initial pump. The bear case is that OpenAI is effectively its only client and its valuation on $510M of 2025 revenue rests on hopes it can challenge Nvidia. x.com x.comÂ